Endocrine toxicities of immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T lymphocyte antigen 4 (CTLA4) or PD1 and its ligand PDL1. ICIs, such as nivolumab, pembrolizumab and ipilimumab,...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nature reviews. Endocrinology Ročník 17; číslo 7; s. 389 - 399
Hlavní autori:	Wright, Jordan J, Powers, Alvin C, Johnson, Douglas B
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Nature Publishing Group 01.07.2021
Predmet:	Adrenal glands Adverse events Antineoplastic Agents, Immunological - adverse effects Cancer Cell activation CTLA-4 protein Cytotoxicity Diabetes mellitus Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - immunology Endocrine disorders Endocrine System Diseases - chemically induced Endocrine System Diseases - diagnosis Endocrine System Diseases - epidemiology Endocrine System Diseases - therapy Epidemiology Humans Hypothyroidism Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune System - drug effects Immune System - physiology Immunotherapy Immunotherapy - adverse effects Lymphocytes T Monoclonal antibodies Morbidity Neoplasms - drug therapy Neoplasms - epidemiology Neoplasms - immunology Pancreas PD-1 protein Pembrolizumab Pituitary Signal transduction Thyroid Thyrotoxicosis
ISSN:	1759-5029, 1759-5037, 1759-5037
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!